Pfizer Submits COVID-19 Oral Antiviral Candidate to FDA for Emergency Use Authorization

Pfizer’s PAXLOVID oral solid-dosage treatment is designed to combat SARS-CoV-2 in high-risk patients at the first sign of infection.